| Literature DB >> 35192689 |
Sharon Baumel-Alterzon1,2, Liora S Katz1, Gabriel Brill1, Clairete Jean-Pierre1, Yansui Li1, Isabelle Tse1, Shyam Biswal3, Adolfo Garcia-Ocaña1,2, Donald K Scott1,2.
Abstract
Finding therapies that can protect and expand functional β-cell mass is a major goal of diabetes research. Here, we generated β-cell-specific conditional knockout and gain-of-function mouse models and used human islet transplant experiments to examine how manipulating Nrf2 levels affects β-cell survival, proliferation, and mass. Depletion of Nrf2 in β-cells results in decreased glucose-stimulated β-cell proliferation ex vivo and decreased adaptive β-cell proliferation and β-cell mass expansion after a high-fat diet in vivo. Nrf2 protects β-cells from apoptosis after a high-fat diet. Nrf2 loss of function decreases Pdx1 abundance and insulin content. Activating Nrf2 in a β-cell-specific manner increases β-cell proliferation and mass and improves glucose tolerance. Human islets transplanted under the kidney capsule of immunocompromised mice and treated systemically with bardoxolone methyl, an Nrf2 activator, display increased β-cell proliferation. Thus, by managing reactive oxygen species levels, Nrf2 regulates β-cell mass and is an exciting therapeutic target for expanding and protecting β-cell mass in diabetes.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35192689 PMCID: PMC9044139 DOI: 10.2337/db21-0581
Source DB: PubMed Journal: Diabetes ISSN: 0012-1797 Impact factor: 9.337